curacle co.,ltd. (KOSDAQ:365270)

Market Cap	279.30B +194.9%
Revenue (ttm)	7.10M -99.6%
Net Income	-18.11B
EPS	-1,120.22
Shares Out	21.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	195,197
Average Volume	450,793
Open	12,620
Previous Close	12,900
Day's Range	12,300 - 13,620
52-Week Range	3,600 - 20,750
Beta	2.21
RSI	38.02
Earnings Date	n/a

About curacle co.,ltd.

curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company’s products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- β/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 365270

Financial Performance

In 2025, curacle co.,ltd.'s revenue was 7.10 million, a decrease of -99.57% compared to the previous year's 1.63 billion. Losses were -18.11 billion, 21.7% more than in 2024.